Maíra Terrra Garcia

Mrs. Maíra Terrra Garcia


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 January 2023 in Microorganisms
Verified
Journal Article
Open access
PDF file
PCPaulo Henrique Fonseca do Carmo
Paulo Henrique Fonseca do Carmo
MGMaíra Terrra Garcia
Maíra Terrra Garcia
LFLívia Mara Alves Figueiredo-Godoi
Lívia Mara Alves Figueiredo-Godoi
ALAnna Carolina Pinheiro Lage
Anna Carolina Pinheiro Lage
NSNewton Soares da Silva
Newton Soares da Silva
Juliana JunqueiraJuliana Junqueira
Juliana Junqueira
Candidiasis is an opportunistic mycosis with high annual incidence worldwide. In these infections, Candida albicans is the chief pathogen owing to its multiple virulence factors. C. albicans infections are usually treated with azoles, polyenes and echinocandins. However, these antifungals may have limitations regarding toxicity, relapse of infections, high cost, and emergence of antifungal resistance. Thus, the development of nanocarrier systems, such as metal nanoparticles, has been widely investigated. Metal nanoparticles are particulate dispersions or solid particles 10–100 nm in size, with unique physical and chemical properties that make them useful in biomedical applications. In this review, we focus on the activity of silver, gold, and iron nanoparticles against C. albicans. We discuss the use of metal nanoparticles as delivery vehicles for antifungal drugs or natural compounds to increase their biocompatibility and effectiveness. Promisingly, most of these nanoparticles exhibit potential antifungal activity through multi-target mechanisms in C. albicans cells and biofilms, which can minimize the emergence of antifungal resistance. The cytotoxicity of metal nanoparticles is a concern, and adjustments in synthesis approaches or coating techniques have been addressed to overcome these limitations, with great emphasis on green synthesis.

1 December 2018 in Photodiagnosis and Photodynamic Therapy
Verified
Journal Article
Closed access
MGMaíra Terrra Garcia
Maíra Terrra Garcia
APAndré Henrique Correia Pereira
André Henrique Correia Pereira
LGLívia Mara Alves Figueiredo Godoi
Lívia Mara Alves Figueiredo Godoi
AJAntonio Olavo Cardoso Jorge
Antonio Olavo Cardoso Jorge
JFJuliana Ferreira-Srixino
Juliana Ferreira-Srixino
Juliana JunqueiraJuliana Junqueira
Juliana Junqueira

1 June 2021 in Photodiagnosis and Photodynamic Therapy
Verified
Journal Article
Closed access
MGMaíra Terrra Garcia
Maíra Terrra Garcia
CSCheyenne Marçal de Souza
Cheyenne Marçal de Souza
NGNathalia Maria Ferreira Gonçalves
Nathalia Maria Ferreira Gonçalves
APAndré Henrique Correia Pereira
André Henrique Correia Pereira
PBPatrícia Pimentel de Barros
Patrícia Pimentel de Barros
JJJuliana Campos Junqueira
Juliana Campos Junqueira

4 May 2022 in Antibiotics
Verified
Journal Article
Open access
PDF file
LGLívia Mara Alves Figueiredo Godoi
Lívia Mara Alves Figueiredo Godoi
MGMaíra Terrra Garcia
Maíra Terrra Garcia
Juliana Guerra PintoJuliana Guerra Pinto
Juliana Guerra Pinto
JFJuliana Ferreira-Srixino
Juliana Ferreira-Srixino
EFEliseu Gabriel Faustino.
Eliseu Gabriel Faustino.
Juliana JunqueiraJuliana Junqueira
Juliana Junqueira
Antimicrobial photodynamic therapy (aPDT) is considered a promising alternative strategy to control Acinetobacter baumannii infections. In this study, we evaluated the action of aPDT mediated by a new photosensitizer derivative from chlorin e-6 (Fotoenticine—FTC) on A. baumannii, comparing its effects with methylene blue (MB). For this, aPDT was applied on A. baumannii in planktonic growth, biofilms, and burn infections in Galleria mellonella. The absorption of FTC and MB by bacterial cells was also evaluated using microscopic and spectrophotometric analysis. The results of planktonic cultures showed that aPDT reduced the number of viable cells compared to the non-treated group for the reference and multidrug-resistant A. baumannii strains. These reductions varied from 1.4 to 2 log10 CFU for FTC and from 2 log10 CFU to total inhibition for MB. In biofilms, aPDT with MB reduced 3.9 log10 CFU of A. baumannii, whereas FTC had no effect on the cell counts. In G. mellonella, only MB-mediated aPDT had antimicrobial activity on burn injuries, increasing the larvae survival by 35%. Both photosensitizers were internalized by bacterial cells, but MB showed a higher absorption compared to FTC. In conclusion, MB had greater efficacy than FTC as a photosensitizer in aPDT against A. baumannii.

17 June 2025 in Microorganisms
Verified
Journal Article
Open access
PDF file
Laura Beatriz Borim da SilvaLaura Beatriz Borim da Silva
Laura Beatriz Borim da Silva
ICIvana Giovannetti Castilho
Ivana Giovannetti Castilho
Fabiana Alves de Souza SilvaFabiana Alves de Souza Silva
Fabiana Alves de Souza Silva
Mahmoud A. GhannoumMahmoud A. Ghannoum
Mahmoud A. Ghannoum
MGMaíra Terrra Garcia
Maíra Terrra Garcia
PCPaulo Henrique Fonseca do Carmo
Paulo Henrique Fonseca do Carmo
The global burden of fungal infections is rising at an alarming rate, with superficial, cutaneous, and mucosal mycoses among the most prevalent. Conventional treatments rely on oral and topical antifungal agents; however, these therapies are often limited by adverse effects, toxicity, frequent recurrence, and poor patient adherence due to prolonged treatment regimens. Moreover, the emergence of antifungal resistance and multidrug-resistant species such as Candidozyma auris and Trichophyton indotineae highlights the urgent need for alternative therapeutic strategies, such as antimicrobial photodynamic therapy (aPDT). aPDT is based on photophysical and photochemical processes involving a photosensitizer (PS), a light source, and molecular oxygen. When combined, these elements generate reactive oxygen species that selectively destroy microbial cells. In this review, we explore various PSs and their effectiveness in aPDT against infections caused by dermatophytes, Candida spp., and other pathogenic fungi. Promisingly, aPDT has demonstrated antifungal activity against both susceptible and resistant strains. In addition, aPDT has been successfully used in cases of mycoses unresponsive to conventional therapies, showing favorable clinical outcomes and overall safety. Current evidence supports aPDT as a valuable strategy for the management of cutaneous, mucosal, and superficial fungal infections and as a potential strategy to combat antifungal resistance.

1 September 2017 in Microbial Pathogenesis
Verified
Journal Article
Closed access
JSJéssica Diane dos Santos
Jéssica Diane dos Santos
JAJanaína Araújo de Alvarenga
Janaína Araújo de Alvarenga
RRRodnei Dennis Rossoni
Rodnei Dennis Rossoni
MGMaíra Terrra Garcia
Maíra Terrra Garcia
RMRenata Mendonça Moraes
Renata Mendonça Moraes
Juliana JunqueiraJuliana Junqueira
Juliana Junqueira